Publication:

Nanotechnology based drug delivery in cancer treatment: enabling controlled and targeted release of medications

The advent of nanotechnology in drug delivery has revolutionized cancer treatment, offering controlled and targeted release of therapeutic agents. This study investigates the impact and effectiveness of various nanoparticle-grounded drug delivery systems (DDSs) in cancer therapy. A qualitative analysis of secondary literature was conducted to explore the types, targeting mechanisms, and clinical applications of nanoparticles (NPs) in cancer treatment. The study categorized NPs into organic, inorganic, and hybrid types and examined their roles in passive and also active targeting of cancer cells. The findings reveal the significant diversity and efficacy of NPs in enhancing drug delivery efficiency while minimizing systemic toxicity. Notable examples of clinically approved nanotherapeutic formulation medications include Doxil®, Myocet®, and Abraxane®, which have shown improved drug pharmacokinetics and biodistribution. Nanotechnology offers transformative potential in cancer therapy, providing promising avenues for the development of advanced and personalized cancer therapeutics.